Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
July 29 2021 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is genetically engineering red blood
cells to create an entirely new class of cellular medicines called
Red Cell Therapeutics™ for the treatment of cancer and autoimmune
diseases, today announced the appointment of Dannielle Appelhans as
chief operating officer, effective August 9, 2021. She will oversee
corporate strategy and technical operations.
“Dannielle brings significant experience driving corporate
strategy for biopharmaceutical organizations as they evolve from
early- to late-stage development, with a particular focus on
clinical and commercial manufacturing and scaling supply chains,”
said Pablo J. Cagnoni, M.D., president and chief executive officer
at Rubius Therapeutics. “As Rubius looks to the future, Dannielle’s
contributions will be critical as we expand our reach to serve more
patients globally.”
Most recently, Ms. Appelhans served as senior vice president of
technical operations and chief technical officer at Novartis Gene
Therapies, where she oversaw late-stage development, clinical and
commercial manufacturing, supply chain and all supporting
operational functions for the gene therapy unit and AAV portfolio.
Since 2014, she held positions of increasing responsibility in
global supply chain, strategy and operational excellence across
several divisions within Novartis. Before joining Novartis, Ms.
Appelhans was a senior engagement manager at McKinsey &
Company, working in the pharmaceutical operations practice. Earlier
in her career she held roles of increasing responsibility at Eli
Lilly and Company.
“With its first cancer medicines in the clinic, Rubius has an
exciting opportunity to lay the foundation for significant growth
as the company scales the organization to reach more patients,”
said Dannielle Appelhans, incoming chief operating officer at
Rubius Therapeutics. “I look forward to joining a remarkable team
and applying my experience and passion for growing global
organizations to deliver on the promise of Rubius’ unique pipeline
of Red Cell Therapeutics™.”
Ms. Appelhans has an MBA from MIT Sloan School of Management, a
Master of Science from Massachusetts Institute of Technology and a
Bachelor of Science from the University of Michigan in mechanical
engineering.
About Rubius TherapeuticsRubius Therapeutics is
a clinical-stage biopharmaceutical company developing a new class
of medicines called Red Cell Therapeutics™. The Company’s
proprietary RED PLATFORM® was designed to genetically engineer and
culture Red Cell Therapeutics™ that are selective, potent and
off-the-shelf allogeneic cellular therapies for the potential
treatment of several diseases across multiple therapeutic areas.
Rubius’ initial focus is to advance RCT™ product candidates for the
treatment of cancer and autoimmune diseases by leveraging two
distinct therapeutic modalities — potent cell-cell interaction and
tolerance induction. Rubius Therapeutics was named among the
2020 Top Places to Work in Massachusetts by the Boston Globe, and
its manufacturing site was recently named 2021 Best
Places to Work in Rhode Island by Providence Business News.
For more information, visit www.rubiustx.com, follow us on Twitter
or LinkedIn or like us on Facebook.
Forward Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, statements regarding our
expectations with respect to the therapeutic potential of our
pipeline of Red Cell Therapeutics, including RTX-240, our
expectations regarding the timing, enrollment, data from and
success of the future cohorts and phases of the clinical trial of
RTX-240, including the Phase 1/2 clinical trial of RTX-240, our
expectations regarding the biological effects of RTX-240 on innate
and adaptive immunity and the related therapeutic benefits,
including the therapeutic window, and beliefs about the safety and
efficacy profile of RTX-240 and its potential role in the treatment
of cancer, and our expectations regarding our strategy, business
plans and focus. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management’s current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
development of our Red Cell Therapeutic product candidates,
including RTX-240, and their therapeutic potential and other risks
identified in our filings with the U.S. Securities and Exchange
Commission (SEC), including our Quarterly Report on Form 10-Q for
the quarter ended March 31, 2021, and subsequent filings with the
SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing our views as of any subsequent date. We
explicitly disclaim any obligation to update any forward-looking
statements.
Contacts:
InvestorsElhan Webb, CFA, Vice President of
Investor Relationselhan.webb@rubiustx.com
Media Marissa Hanify, Director, Corporate
CommunicationsMarissa.hanify@rubiustx.com
Dan Budwick, 1AB+1 (973) 271-6085dan@1abmedia.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Jul 2023 to Jul 2024